

## COSMETIC PRODUCT SAFETY REPORT

**In accordance with Annex I, EC 1223/2009 and The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019**

<b>Report Number</b>	240050-1 (243864)	<b>Date:</b>	16 September 2024
<b>Product type:</b>	Melt and pour soap	<b>Responsible person details:</b>	Joe D'Arcy, 20 Heron Road, Bristol, BS5 0LU, United Kingdom
<b>Product name/code:</b>	Blue Cedar & Pine with Oats		
<b>Product category:</b>	Solid soap – Rinse off	<b>Email address:</b>	

### SUMMARY

The product(s) have been reviewed and according to the information submitted in this report the product complies with EU Regulation (EC) No 1223/2009 and its subsequent amendments to date. The product(s) have been reviewed and according to the information submitted in this report the product complies with The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019 and its subsequent amendments to date. The ingredients in this product are used at levels that are consistent with industry norms.

**It is my opinion that these cosmetic formulation(s) are considered safe to use under normal or reasonably foreseeable conditions of use. The assessment is conditional on the items outlined in section B.**

**Signed:**



**Laura Turnham, ERT, RSB CBiol, MSc**

## INDEX

### **PART A – COSMETIC PRODUCT SAFETY INFORMATION**

1. Quantitative and qualitative composition of the cosmetic product
2. Physical/chemical characteristics and stability of the cosmetic product
3. Microbiological quality
4. Impurities, traces, information about the packaging material
5. Normal and reasonably foreseeable use
6. Exposure to the cosmetic product
7. Exposure to the substances
8. Toxicological profile of the substances
9. Undesirable effects and serious undesirable effects
10. Information on the cosmetic product

### **PART B – COSMETIC PRODUCT SAFETY ASSESSMENT**

1. Assessment conclusion
2. Labelled warnings and instructions of use
3. Reasoning
4. Assessor's credentials and approval of part B

#### **Annexes**

- I. Toxicological Ingredient Profiles
- II. Fragrance information
- III. General notes

## PART A COSMETIC PRODUCT SAFETY INFORMATION

### I. Quantitative and qualitative composition of the cosmetic product(s)

Product name: Blue Cedar & Pine with Oats soap

Ingredients	
INCI names	% INCI
Sodium Palmate	51.638456
Aqua	16.051030
Sodium Palm Kernelate	16.051030
Glycerin	6.879013
Butyrospermum Parkii Butter	5.002918
*****	
Citrus Aurantium Dulcis Peel Oil	0.658718
Sodium Chloride	0.091720
Avena Sativa Kernel Meal	0.300175
Illite	0.375219
Kaolin	0.595347
Montmorillonite	0.030018
Tetrasodium Glutamate Diacetate	0.458601
Citric Acid	0.091720
Sodium Citrate	0.458601
Pinus Sylvestris Oil	0.658718
Juniperus Mexicana Wood Oil	0.658718

Additional labeling requirements In accordance with article 19, paragraph 1, letter g, of Regulation (EC) No. 1223/2009

Labeling allergens	
INCI names	% INCI
Limonene	0.698241

Non-labeling allergens	
INCI names	% INCI
Citral	0.000988
Linalool	0.002701

Total %: 100.000000



Allergen declarations above are based on the information on the date of submission. It is the duty of the Responsible Person to ensure that the ingredient and allergen declarations are correct on the label.

**For the EU:**

**Cosmetic products containing additional allergens listed in COMMISSION REGULATION (EU) 2023/1545 will need to be declared on the labelling, when its concentration exceeds:**

— 0,001 % in leave-on products

— 0,01 % in rinse-off products.

Products that do not comply with the restriction(s) may be placed on the Union market until 31 July 2026 and made available on the Union market until 31 July 2028. It is the duty of the Responsible Person when placing a cosmetic on sale in the EU to comply with this requirement by the implementation date.

## 2. Physical/chemical characteristics and stability of the cosmetic product

A product specification was not provided.

Product name:	Description
Blue Cedar & Pine with Oats soap	Solid soap with a characteristic fragrance.

The product was tested for stability in an in-house method. Stability data was not provided.

The responsible person must ensure that the product is sold with an appropriate expiry date.

There is a long history of stability of vegetable derived cold processed soaps. Stability is not expected to be a safety concern, provided that there is no excess lye in the formulation, and that the product is cured for a suitable length of time, typically 4-6 weeks. Rancidification of cold process soaps can occur under certain conditions, but it is a quality and aesthetic concern, not a safety concern.

### 3. Microbiological quality

The product(s) is a low risk for microbiological growth as the product is a soap-based formulation with low water availability. The product is likely to provide an environment that would deny microorganisms the physical and chemical requirements for growth and survival.

According to the principles outlined in ISO 29621:2017 this product would be considered a low microbiological risk and does not require a microbiological challenge test.

A microbiological specification was not provided. It is the duty of the responsible person to ensure that the product complies with the microbiological specifications outlined by SCCS/1628/21:

Types of microorganisms	Products specifically intended for children under three years of age, the eye area or the mucous membranes	Other products
Total Aerobic Mesophilic Microorganisms (Bacteria plus yeast and mould)	≤100 CFU / g or mL <sup>a</sup>	≤1000 CFU / g or mL <sup>b</sup>
<i>Escherichia coli</i>	Absence in 1 g or 1 ml	Absence in 1 g or 1 ml
<i>Pseudomonas aeruginosa</i>	Absence in 1 g or 1 ml	Absence in 1 g or 1 ml
<i>Staphylococcus aureus</i>	Absence in 1 g or 1 ml	Absence in 1 g or 1 ml
<i>Candida albicans</i>	Absence in 1 g or 1 ml	Absence in 1 g or 1 ml

Due to inherent variability of the plate count method, according to USP Chapter 61 or EP Chapter 2.6.12, Interpretation of results, results considered out of limit if  
a > 200 CFU/g or ml, b > 2 000 CFU/g or ml.

#### 4. Impurities, traces, information about the packaging material quality

Toxicologically relevant impurities of the raw materials will be discussed in Annex I.

The product may be placed in the following primary packaging:

Food safe pouches/wrap  
Food safe cellophane  
Wax paper  
Paper  
Cardboard

The product may be placed in the following secondary packaging:

Paper  
Cardboard  
Cloth bags (for example: bamboo, cotton, sisal).

The responsible person must ensure that the packaging is food or cosmetic grade.

The responsible person must ensure that the packaging is compatible with the product.

It is not expected that heavy metal impurities will be present in the raw materials in significant amounts. Therefore, heavy metals are expected to be below acceptable limits. According to Health Canada guidance (2012) "technically unavoidable" limits for cosmetics are considered to be:

Lead:	10 ppm
Arsenic:	3 ppm
Cadmium	3 ppm
Mercury	1 ppm
Antimony	5 ppm

#### 5. Normal and reasonably foreseeable use

It is expected that consumers will moisten the bar with water, bring to a lather and wash their body with the soap, followed by rinsing.

It is foreseeable that consumers may also apply the product to their face followed by rinsing.

Should the product enter the eyes it is expected that the product will cause irritation. It is expected that consumers will be aware of this risk and should rinse their eyes should this occur.

Ingestion would be considered misuse and will not be covered in this report.

The Responsible Person must ensure that the product does not mimic foodstuffs in order to ensure consumer safety and to comply with local and regional laws/ regulations.

Inhalation is not expected as the product is not expected to generate respirable particles during use.



## 6. Exposure to the cosmetic product

Product type:	Solid soaps	
Use per day (g)	2.60	Source: US EPA Exposure Factors Handbook, 2011
Retention factor:	0.01	
Site of application:	Total body area	
Skin exposure (cm <sup>2</sup> )	17500.00	Source: SCCS Notes of Guidance, 12th Revision
IFRA 49th Amendment Class	9	
IFRA 49th Amendment Consumer Exposure Level Estimate µg/cm <sup>2</sup> /day	200	
Frequency of application	3.0/day (US EPA Exposure Factors Handbook, 2011)	
Calculated relative daily exposure (mg/kg bw/day)	43.33	
Body weight (kg)	60.00	Default value
IFRA QRA2 Aggregate Adjustment Factor	0.5	

## 7. Exposure to the substances

Product type:		Solid soaps NESIL--No Expected Sensitization Induction Level														
Product use per day (g)		2.6000 AEL-Acceptable Exposure Level														
Retention factor:		0.0100 CEL--Consumer Exposure Level														
Skin exposure (cm2)		17500.0000														
Body weight		60.0000														
INCI Name	Blue Cedar & Pine with Oats Soap (% w/w)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Level Present in Product(s) (% w/w)	Systemic Exposure Dose (mg/kg bw/day)	Point of Departure (mg/kg bw/day)	Margin of Exposure	Apply skin penetration data? (Tick applies skin penetration data on all ingredients)	Skin penetration (%)	Dermal exposure ug/cm2	NESIL	Safety Factor	AEL/CEL	Acceptable Exposure Level ug/cm2
Aqua	16.0510	7732-18-5	231-791-2	Solvent	N/A	16.05103	0.06955	No Data			100	0.238	No Data	300		
Avena Sativa Kernel Meal	0.3002	84012-26-0	281-672-4	Abrasive, Absorbent, Bulking	N/A	0.30018	0.00130	No Data			100	0.004	No Data	300		
Butyrospermum Parkii Butter	5.0029	194043-92-0 - 91080-23-8	293-515-7	Skin Conditioning, Viscosity Controlling	N/A	5.00292	0.02168	No Data			100	0.074	No Data	300		
Citric Acid	0.0917	77-92-9 / 5949-29-1	201-069-1	Buffering, Chelating, Masking	N/A	0.09172	0.00040	1200	3019222		100	0.001	No Data	300		
Citrus Aurantium Dulcis Peel Oil	0.6587	8008-57-9	N/A	Astringent, Masking, Skin Conditioning, Tonic	N/A	0.65872	0.00285	375	131374		100	0.010	No Data	300		
Glycerin	6.8790	56-81-5	200-289-5	Denaturant, Hair Conditioning, Humectant, Oral Care, Perfuming, Skin Protecting, Viscosity Controlling	N/A	6.87901	0.02981	10000	335469		100	0.102	No Data	300		
Illite	0.3752	12173-60-3	N/A	Abrasive, Absorbent, Anticaking, Bulking	N/A	0.37522	0.00163	No Data			100	0.006	No Data	300		
Juniperus Mexicana Wood Oil	0.6587	91722-61-1	294-461-7	Perfuming	N/A	0.65872	0.00285	No Data			100	0.010	No Data	300		
Kaolin	0.5953	1332-58-7	310-194-1	Abrasive, Absorbent, Anticaking, Bulking, Cosmetic Colorant, Opacifying	IV/119	0.59535	0.00258	10000	3876214		100	0.009	No Data	300		
Montmorillonite	0.0300	1318-93-0	215-288-5	Absorbent, Bulking, Emulsion Stabilising, Stabilising, Viscosity Controlling	N/A	0.03002	0.00013	1000	7687695		100	0.000	No Data	300		
Pinus Sylvestris Oil	0.6587	84012-35-1 / 94266-48-5	281-679-2 / 304-455-9	Masking, Perfuming	III/110	0.65872	0.00285	No Data			100	0.010	No Data	300		
Sodium Chloride	0.0917	7647-14-5	231-598-3	Bulking, Masking, Oral Care, Viscosity Controlling	N/A	0.09172	0.00001	50	4193364		3	0.001	No Data	300		
Sodium Citrate	0.4586	68-04-2 / 6132-04-3	200-675-3	Buffering, Chelating, Masking	N/A	0.45860	0.00199	No Data			100	0.007	No Data	300		
Sodium Palm Kernelate	16.0510	61789-89-7	263-097-0	Cleansing, Emulsifying, Surfactant, Viscosity Controlling	N/A	16.05103	0.06955	1000	14377		100	0.238	No Data	300		
Sodium Palmate	51.6385	61790-79-2	263-162-3	Cleansing, Emulsifying, Surfactant, Viscosity Controlling	N/A	51.63846	0.22377	1000	4469		100	0.767	No Data	300		
Tetrasodium Glutamate Diacetate	0.4586	51981-21-6	257-573-7	Chelating	N/A	0.45860	0.00199	300	150961		100	0.007	No Data	300		
Limonene	0.6982	138-86-3	205-341-0/931-893-3	Deodorant, Perfuming, Solvent	III/88 III/167 III/168	0.69824	0.00000	150	30984453		0.16	0.010	10000	300	1607	16.67
Citral	0.0010	5392-40-5	226-394-6	Flavouring, Perfuming	III/70	0.00099	0.00000	200	46714419		100	0.000	1400	300	158959	2.33
Linalool	0.0027	78-70-6	201-134-4	Deodorant, Perfuming	III/84	0.00270	0.00000	117	5880175099		0.17	0.000	15000	300	622989	25.00



Swift Fox Consultancy Ltd  
36 Northampton Road,  
Market Harborough,  
Leics,  
United Kingdom,  
LE16 9HE



## **8. Toxicological profile of the substances**

The raw materials in this product were from recognised cosmetic, food or pharmaceutical grade ingredient suppliers. The responsible person is responsible for retaining all Certificates of Analysis (COAs), Technical documentation, MSDSs and retaining the information for the Product Information File (PIF). IFRA and allergen statements must be kept up to date and retained in the PIF file by the responsible person.

Toxicological profiles of ingredients found in Annex I of this document. Technically unavoidable traces of prohibited or restricted chemicals are also addressed in Annex I.

## **9. Undesirable effects and serious undesirable effects**

No reports of undesirable or serious undesirable effects have been submitted. In the event that adverse reaction(s) occur the responsible person should inform the safety assessor so that the safety assessment can be updated and reviewed.

## **10. Additional information on the cosmetic product**

The product must be manufactured according to the principles of GMP (Good Manufacturing Practice). It is recommended that the product is manufactured according to the principles outlined in ISO 22716: 2007.

## PART B – COSMETIC PRODUCT SAFETY ASSESSMENT

### 1. Assessment conclusion

This product has been reviewed and according to the information submitted in this report. The product complies with EU Regulation (EC) No 1223/2009 and its subsequent amendments to date. The product has been reviewed and according to the information submitted in this report the product complies with The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019 and its subsequent amendments to date.

This report has reviewed the following:

- Microbiological safety, stability and physicochemical status of the product
- Packaging.
- Toxicological impurities in the packaging materials/raw materials.
- Systemic toxicity.
- Developmental/reproductive toxicity.
- Carcinogenicity/mutagenicity.
- Allergy (Type I, IV).
- Skin and eye irritancy.
- Photosensitivity and photosensitisation.

The product is considered safe and unlikely to cause an unreasonable level of adverse effects if used under normal and reasonably foreseeable conditions.

### 2. Labelled warnings and instructions of use

Mandatory label requirements: None.

Non mandatory but advisable warning statement:

“If product enters the eyes, rinse well with clean water.”

“Keep out of reach of children.”

Directions for use:

Directions for use were not provided for review.

Warnings:

Warnings were not provided for review.



### 3. Reasoning

The product has been reviewed and according to the information submitted in this report the product complies with EU Regulation (EC) No 1223/2009 and its subsequent amendments to date. The product has been reviewed and according to the information submitted in this report the product complies with The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019 and its subsequent amendments to date. The ingredients in this product are used at levels that are consistent with industry norms.

The Responsible Person must ensure that the purity/impurity criteria for ingredients outlined in Annex I are adhered to.

The Responsible Person must ensure that the product is manufactured in accordance with GMP.

The Responsible Person is responsible for the maintenance of the PIF (Product Information File).

The product is considered safe and unlikely to cause an unreasonable level of adverse effects if used under normal and reasonably foreseeable conditions.

#### 4. Assessor's credentials and approval of part B

The product has been reviewed and according to the information submitted in this report the product complies with EU Regulation (EC) No 1223/2009 and its subsequent amendments to date.

The product has been reviewed and according to the information submitted in this report the product complies with The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019 and its subsequent amendments to date

The ingredients in this product are used at levels that are consistent with industry norms.

It is my opinion that this cosmetic formulation is considered safe to use under normal or reasonably foreseeable conditions of use. The assessment is conditional on the items outlined in section B.

Signed:



Laura Turnham, ERT, RSB CBiol, MSc

##### Qualifications:

Safety assessment of cosmetics in the EU, VUB (University of Brussels), 2015, Pass

MSc Molecular Pathology and Toxicology, Leicester University (UK), 2011. Distinction.

BSc Biochemistry (Toxicology), University of Surrey, 2008, 2:1 (Hons).

Eurotox registered toxicologist (ERT).

UK Registered Toxicologist (UKRT).

Chartered Biologist (CBiol RSB).

Member of the Royal Society of Biology (MRSB).

## Annex I – Toxicological Ingredient Profiles

### Ingredient Profile: Avena Sativa (Oat) Kernel Meal

**CAS number:** N/A **EC number:** N/A  
**INCI Name:** Avena Sativa Kernel Meal  
**Pseudonyms:** Oatmeal Powder  
**Structure:** N/A **Image:**



**CLP Hazard classification(s):** Not classified  
**REGULATION (EC) No 1223/2009** Not restricted.  
**Other regulatory statuses:** N/A

INCI Name	Sub Code & Pse with Date Stamp (N/A)	CAS Number	EC Number	Paraben(s)	Maximum Level Systemic Exposure (% dose mg/kg bw/day)	Potential of Systemic Exposure (mg/kg bw/day)	Margin of Exposure	Apply this classification data (1) to all uses unless otherwise specified	Safe concentration (%)	Dermal exposure (mg/kg bw/day)	NEEL	Safety Factor	ADJCEL	Acceptable Exposure Level (mg/kg bw/day)
Avena Sativa Kernel Meal	0.3002	64012-36-0	281-672-4	Abrasive, Absorbent, Bulking	N/A	0.30016	0.00130 No Data	23	100	0.004 No Data	300			

Avena Sativa (Oat) Kernel Meal is a coarse meal obtained by the grinding of the kernels of oats, Avena sativa. It is used as an abrasive agent, absorbent agent, and bulking agent in cosmetic products.

Oats have a long history of use as a major stable foodstuff. Oats are a major constituent of the diets, particularly in Western diets, therefore, systemic toxicity is not expected.

According to the CIR review<sup>1</sup> Avena Sativa Kernel Flour is used at up to 1% in rinse off products.

Reading across to Avena Sativa Kernel Flour:

In a human irritation test of a product containing 1% Avena Sativa Kernel Flour in 45 patients with atopic dermatitis for 4 weeks found that the product was well tolerated with no reported adverse effects. In a study of the same product in 1607 babies with mild to moderate dermatitis adverse effects were reportedly low (2.4%) and not product related. In a HRIPT a product containing 1% Avena Sativa Kernel Flour was not sensitising or irritating in 51 individuals. In a HRIPT of a product containing 1% Avena Sativa Kernel Flour in 56 individuals was not irritating or sensitising.

Avena sativa containing products have been well tested for irritation, phototoxicity and sensitisation at concentrations of 1-43.3%. Skin sensitisation was rare (2/5725 reactions), no phototoxicity, no photosensitisation, no skin or eye irritation was observed<sup>1</sup>.

The CIR reviewed the potential for type I irritation because oats are not a major food allergen and the ingredients reviewed did not have the same properties of wheat protein in the ability to induce type I hypersensitivity<sup>1</sup>.

Summary:

The concentration and use of Avena Sativa (Oat) Kernel Meal is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with



industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

References:

- I. CIR, Safety Assessment of Avena sativa (Oat)-Derived Ingredients as Used in Cosmetics, 2015

Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.



## Ingredient Profile: Butyrospermum Parkii (Shea) Butter

**CAS number:** 91080-23-8 / 194043-92-0 **EC number:** 293-515-7 (I)

**INCI Name:** Butyrospermum Parkii Butter

**Pseudonyms:** Butyrospermum Parkii (Shea) Butter, Karite Butter.

**Structure:** N/A

**Image:**



**CLP Hazard classification(s):** Not classified

**REGULATION (EC) No 1223/2009** Not restricted.

**Other regulatory statuses:** N/A

INCI Name	Blue Circle & Plus with Data Sheet (2016)	CAS Number	EC Number	Pseudonyms	Restrictions	Maximum Lead Exposure: Product or Product(s) (%) (Shea (high health))	Point of Exposure (mg/kg bodyweight)	Marginal Exposure	Applies also to products that are not intended for use as food or feed	San. penetration (%)	Dermal exposure (mg/cm²)	MSL	Target Dose	ABL/CC	Accumulative Exposure Level (mg/kg)
Butyrospermum Parkii Butter	5,0079	91080-23-8 / 194043-92-0	793-515-7	Skin Conditioning, Viscosity Controlling	N/A	5,0079	0.07168 No Data			100	0.07168 No Data				

Butyrospermum Parkii (Shea) Butter is a fat obtained from the fruit of Butyrospermum parkii. The accepted scientific name for Butyrospermum parkii is Vitellaria paradoxa. It is used as a skin conditioning agent, an occlusive agent and viscosity increasing agent in cosmetic products.

According to the CIR review<sup>1</sup>, Butyrospermum Parkii (Shea) Butter typically contains; myristic acid (0.5%), palmitic acid (3-9%), stearic acid (30-50%), oleic acid (38-50%), linoleic acid (3-8%) linolenic acid (0.5%) and arachidic acid (2.5-3%). Butyrospermum Parkii (Shea) Butter is reported to be used at up to 60% in leave on products, up to 8% in products used in the eye area, up to 26% in products that may be ingested, up to 3% in products that may be inhaled, up to 15% in products that are dermally applied, up to 60% in products used on the nail area, and up to 5% in baby products<sup>1</sup>.

In a HRIPT performed on 111 individuals with a body butter product containing 60% Butyrospermum Parkii (Shea) Butter. No irritation or sensitisation was reported. A body butter massage product containing 45% Butyrospermum Parkii (Shea) Butter was tested in 4 HRIPTs each tested on 109 individuals. No irritation or sensitisation was observed. On the basis of HRIPT and negative results *in vitro* skin irritation assays Butyrospermum Parkii (Shea) Butter is not expected to cause irritation or sensitisation. No reports of contact dermatitis exist in the literature. Protein content of shea butter is very low<sup>2</sup> (0.042%) and no reports of type I allergy exists in the literature. Phototoxicity is not expected.

Vegetable based fatty acids have a long history of safe use in the diet in edible oils, such as rapeseed oil, palm oil, olive oil and other vegetable-based oils. According to JECFA palmitic acid, stearic acid, lauric acid and oleic acid are do not have any safety concerns in the diet<sup>3</sup>. When applied topically fatty acids have been shown to remain mainly on the outer layers of the stratum corneum with little penetration<sup>4</sup>. Therefore, systemic toxicity is not expected.

**Summary:**

The concentration and use of Butyrospermum Parkii (Shea) Butter is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

**References:**

2. IJT 36(Suppl. 3):51-129, 2017
3. Journal of Allergy and Clinical Immunology; 127, Iss. 3, (Mar 2011): 680-682
4. JECFA, WHO Food Additives Series No. 40, 1998.
5. Patzelt, A & Lademann, J & Richter, H & Darvin, Maxim & Schanzer, S & Thiede, Gisela & Sterry, Wolfram & Vergou, Theognosia & Hauser, Matthias. (2011). In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 18. 364-9. 10.1111/j.1600-0846.2011.00578.x.

**Specification data:**

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

**Supporting test data:**

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
<b>Skin irritation</b>	OECD 404	Rabbit: Very slightly irritating at up to 100%	Secondary source: IJT 36(Suppl. 3):51-129, 2017 Animal test date: 1999
<b>Eye irritation</b>	OECD 405	Rabbit: Non irritating at up to 100%	Secondary source: IJT 36(Suppl. 3):51-129, 2017 Animal test date: 1985
<b>Skin sensitisation</b>	OECD 406	Negative in a Maximisation study at up to 75% (induction) and 20% (challenge)	Secondary source: IJT 36(Suppl. 3):51-129, 2017 Animal test date: 1985
<b>Repeated dose 90-day oral toxicity study in rodents</b>	OECD 408	No toxicity observed in rats fed up to 20% in the diet.	Secondary source: JEPT 4(4):105-120, 1980 Animal test date: 1980
<b>Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test</b>	OECD 422	NOAEL rat: 7500 mg/kg bw/day	Secondary source: Safety Assessment of Butyrospermum parkii (Shea)-






			Derived Ingredients as Used in Cosmetics, 2017 Animal test date: 2002
<b>In vitro 3T3 NRU phototoxicity test</b>	OECD 432	Not phototoxic	Secondary source: Safety Assessment of Butyrospermum parkii (Shea)- Derived Ingredients as Used in Cosmetics, 2017 Non animal test
<b>Chronic toxicity studies</b>	OECD 452	NOAEL rat: 7500 mg/kg bw/day	Secondary source: Safety Assessment of Butyrospermum parkii (Shea)- Derived Ingredients as Used in Cosmetics, 2017 Animal test date: 2001
<b>In vitro skin irritation: reconstructed human epidermis test method</b>	OECD 439	Non irritating up to 67.3%	Secondary source: IJT 36(Suppl. 3):51-129, 2017 Non animal test data.
<b>In Chemico skin sensitisation</b>	OECD 442c	Not a sensitiser.	Safety Assessment of Butyrospermum parkii (Shea)- Derived Ingredients as Used in Cosmetics, 2017 Non animal test data.
<b>In vitro bacterial reverse mutation test</b>	OECD 471	Not mutagenic up to 5000 µg/plate ±S9	Secondary source: Safety Assessment of Butyrospermum parkii (Shea)- Derived Ingredients as Used in Cosmetics, 2017 Non animal test data.

## Citric Acid

**Structure:**

$$\begin{array}{c} \text{CH}_2\text{COOH} \\ | \\ \text{HO}-\text{C}-\text{COOH} \\ | \\ \text{CH}_2\text{COOH} \end{array}$$

**Image:**



**Other regulatory statuses:** Food:  
USFDA: GRAS, approved indirect and direct food additive (21CFR178.1010, 21CFR184.1033).  
JECA: Not restricted.  
EU: Approved food additive.

Cosmetics:  
Canada Hotlist: (AHAs)  
FDA: AHAs  
EU: Not restricted

[illegible]

Citric acid when orally administered is well absorbed and metabolised. Citric acid is also produced endogenously as a part of normal metabolism, where it completes the breakdown of pyruvate produced from glucose metabolism. Approximately 2 Kg of citric acid is metabolised every day in



humans. Citric acid is freely filterable in the kidney and 65-90% of citric acid is reabsorbed<sup>2</sup>. Therefore as citric acid is present in the diet naturally in addition to synthetic sources, coupled with endogenous production of citric acid, systemic toxicity from cosmetic products containing citric acid is not expected.

Citric acid has a low acute oral toxicity. Citric acid can cause coughing in humans and in animal models when inhaled in high concentrations, the cough reflex is produced by irritation to the larynx and trachea<sup>2</sup>. In animal models citric acid is slightly irritating to the skin and severely irritating to the eyes. In a 48h patch test of 1% citric acid in 133 oral disease patients there were no reactions to citric acid<sup>2</sup>; however according to the OECD SIDS report<sup>3</sup> citric acid can cause a stinging sensation at 2% aqueous solutions. This effect was not related to irritation, therefore, although it is not necessarily a safety concern, it is recommended to limit the level of citric acid in aqueous cosmetics as high levels of citric acid topically is not always tolerated by the consumer.

Citric acid has been tested in a HRIPT test. Patches of a cuticle cream containing 4% citric acid were applied 3 times a week for 3 weeks followed by a rest period. There were no reports of irritation or sensitisation<sup>2</sup>.

Citric acid is considered an alpha hydroxy acid by the USFDA and Health Canada, at high levels in leave on products it is recommended to place a suncare warning on the labelling.

#### Summary:

The concentration and use of citric acid is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

#### References:

1. Journal of Endourology. 22 (3): 567–570
2. IJT 33(Supl.2):16-46, 2014
3. OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001

#### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

#### Recommended specification:

Appearance: White crystalline powder or crystals  
Lead: <0.5 mg/kg  
Arsenic: <3 mg/kg  
Mercury: <1 mg/kg

#### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
------------	------------	--------	--------





<b>Acute oral toxicity</b>	Not to GLP	Mouse LD <sub>50</sub> : 5400 mg/kg	Secondary source: SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1981
<b>Dermal irritation</b>	OECD 404, not to GLP	Rabbit: Slightly irritating	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1991.
<b>Eye irritation</b>	Draize, not to GLP	Rabbit: At 10%, 30% citric acid was mildly to moderately irritating.	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1984
<b>Reproductive/developmental toxicity</b>	Pre-guideline test data.	Rats NOAEL: 2500 mg/kg bw/day	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1976.
<b>In vitro Bacterial Reverse Mutation Test</b>	OECD 471	Not mutagenic up to 5000 µg/plate ±S9	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: Non animal test method.
<b>Chronic systemic toxicity</b>	Pre-guideline test data.	NOAEL rat: 1200 mg/kg bw/day fed 3 and 5% citric acid in the diet for 2 years.	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1957
<b>Chronic systemic toxicity</b>	Pre-guideline test data.	NOAEL dog: 1380 mg/kg bw/day fed in the diet for up to 120 days.	Secondary source: OECD SIDS Initial Assessment Report for 11th SIAM, Citric acid, 2001 Animal test date: 1946
<b>Supporting data</b>	N/A	In humans a 2% aqueous solution of citric acid can cause a stinging sensation that is not related to irritation.	SIDS Initial Assessment Report for 11th SIAM, 2001
<b>Supporting data</b>	N/A	HRIFT of 60 eczema patients with 2.5% citric acid in petrolatum did not cause any irritant reactions	SIDS Initial Assessment Report for 11th SIAM, 2001

## Ingredient Profile: Citrus Aurantium Dulcis (Orange) Peel Oil

**CAS number:** 8028-48-6 (generic) / 8008-57-9 **EC number:** 232-433-8 (I)

**INCI Name:** Citrus Aurantium Dulcis Peel Oil

**Pseudonyms:** Citrus Aurantium Dulcis (Orange) Peel Oil

**Structure:** N/A

**Image:**



**CLP Hazard classification(s):** Not classified

**REGULATION (EC) No 1223/2009** 11/358: Furocoumarines (e. g. trioxysalen (INN), 8-methoxypsoralen, 5-methoxypsoralen) except for normal content in natural essences used. In sun protection and in bronzing products, furocoumarines shall be below 1 mg/kg.

**Other regulatory statuses:** 21CFR182.20

INCI Name	Size Color & Pic with Data Sheet (% v/v)	CAS Number	EC Number	Preservative	Restrictions	Maximum Allowable Systemic Exposure (% Daily Intake)	Power of Dispersants (mg/kg bodyweight)	Margin of Exposure	Apply when paraben-free product is used in place of parabens	See paraben-free (%)	Dispersant exposure (mg/kg)	NEEL	Subst. Factor	ARCEL	Acceptable Exposure Level (mg/kg)
Citrus Aurantium Dulcis Peel Oil	0.6307	8008 57 9	N/A	Astringent, Masking, Skin Conditioning, Tonic	N/A	0.63072	0.00205	375	131374	2	100	0.010 / No Data	300		

Citrus Aurantium Dulcis (Orange) Peel Oil is the volatile oil obtained by expression from the peel of Citrus sinensis. The accepted scientific name for Citrus aurantium dulcis is Citrus x aurantium. It is used as a fragrance ingredient and skin conditioning agent in cosmetic products. It is considered to be suitable for human consumption by the USFDA (21CFR182.20), who have also granted it GRAS status (Generally Recognised As Safe). Citrus essential oils are also used as flavouring agents in pharmaceutical products. There is a long history of use of the extracts of dried fruit/peel in Chinese and Japanese herbal medicines<sup>1</sup>.

According to the CIR review<sup>1</sup> Citrus Aurantium Dulcis (Orange) Peel Oil is used at up to 0.54% in leave on products, up to 29% in rinse off products, up to 0.1% in products used in the eye area, and up to 0.4% in dermally applied products, and up to 29% in hair, non-colouring products. Citrus Aurantium Dulcis (Orange) Peel Oil has low acute oral and dermal toxicity<sup>2</sup>, undiluted Citrus Aurantium Dulcis (Orange) Peel Oil was irritating in animal studies, however, when tested at 8% on 25 individuals it was non irritating and non-sensitising<sup>2</sup>. Citrus Aurantium Dulcis (Orange) Peel Oil is non-phototoxic to borderline phototoxic depending on the grade of oil<sup>2</sup>. A 100 contact dermatitis patients patch tested with 5% Citrus Aurantium Dulcis (Orange) Peel Oil was not irritating or sensitising. In a study of 200 contact dermatitis patients one was sensitive to 2% Citrus Aurantium Dulcis (Orange) Peel Oil in patch testing (0.5%). In a multicentre patch testing program of 6,246 dermatitis patients only 0.2% tested positive to 2% Citrus Aurantium Dulcis (Orange) Peel Oil. Citrus Aurantium Dulcis (Orange) Peel Oil was not genotoxic in *in vitro* bacterial or mammalian tests.



**Summary:**

The concentration and use of Citrus Aurantium Dulcis (Orange) Peel Oil is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

**References:**

1. IJT 38(Suppl. 2):33-59, 2019
2. Tisserand, Essential Oil Safety, A Guide for Health Care Professionals, 2014

**Specification data:**

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

**Supporting test data:**

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.


Test type:	Guideline:	Result	Source
<b>Acute oral toxicity</b>	OECD 401	Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety, A Guide for Health Care Professionals, 2014 Animal test date: 1974
<b>Acute dermal toxicity</b>	OECD 402	Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety, A Guide for Health Care Professionals, 2014 Animal test date: 1974
<b>Skin irritation</b>	OECD 404	Rabbit: Undiluted sweet orange oil caused moderate irritation.	Secondary source: Tisserand, Essential Oil Safety, A Guide for Health Care Professionals, 2014 Animal test date: 1974
<b>Reproduction/developmental toxicity screening test</b>	OECD 421	Maternal NOAEL rat: 750 mg/kg bw/day Foetal NOAEL rat: 375 mg/kg bw/day	Secondary source: Tisserand, Essential Oil Safety, A Guide for Health Care Professionals, 2014 Animal test date: 1989
<b>In vitro 3T3 NRU phototoxicity test</b>	OECD 432	Borderline phototoxic	Secondary source: IJT 38(Suppl. 2):33-59, 2019 Non animal test method.





<b><i>In vitro</i> bacterial reverse mutation test</b>	OECD 471	Not mutagenic	Secondary source: IJT 38(Suppl. 2):33-59, 2019 Non animal test method.
<b><i>In Vitro</i> mammalian chromosome aberration test</b>	OECD 473	No chromosomal aberrations were observed in CHO cells.	Secondary source: IJT 38(Suppl. 2):33-59, 2019 Non animal test method.
<b><i>In vivo</i> mammalian bone marrow chromosome aberration test</b>	OECD 475	Not genotoxic	Secondary source: IJT 38(Suppl. 2):33-59, 2019 Non animal test method.

## Ingredient Profile: Glycerin

<b>CAS number:</b>	56-81-5	<b>EC number:</b>	200-289-5 (I)
<b>INCI Name:</b>	Glycerin		
<b>Pseudonyms:</b>	Glycerine, Glycerol		
<b>Structure:</b>	C <sub>3</sub> H <sub>8</sub> O <sub>3</sub>	<b>Image:</b>	
<b>CLP Hazard classification(s):</b>	N/A		
<b>REGULATION (EC) No 1223/2009</b>	Not restricted.		
<b>Other regulatory statuses:</b>	Cosmetics: Canada Hotlist. Food: Approved EU food additive - E422		

INCI Name	Blue Color & Blue with Dark Soap (Color)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Level Specified: Preservative (Preservative) (w/v)	Maximum Level Specified: Fragrance (Fragrance) (mg/kg body weight)	Maximum Level Specified: Perfume (Perfume) (mg/kg body weight)	Maximum Level Specified: Mixture of Fragrance (Mixture of Fragrance) (mg/kg body weight)	Apply skin penetration studies (if available) (mg/kg body weight)	Site penetration (mg/kg body weight)	Dermal exposure (mg/kg body weight)	MSL	Safety Factor	ADL/CEL	Acceptable Exposure Level (mg/kg body weight)
Glycerin	6.8/90	56-81-5	700-289-5	Conditioning, Hair Conditioning, Moisturizer, Oral Care, Perfuming, Skin Protecting, Viscosity Controlling	N/A	6.8/90	0.0798	10000	703459	100	0.102 (No Data)	300				

Glycerin is a polyhydric alcohol. Glycerin is classified as GRAS (Generally Recognised as Safe) by the USFDA (21CFR182.90). It is approved for use as an indirect and direct food additive by the USFDA (21CFR175.300, 21CFR172.866. According to the CIR (Cosmetic Ingredient Review Expert Panel) 2014 report glycerine is used at up to 79.2% in leave on products, up to 99.4% in rinse off products, up to 47.9% in products used in the eye area, and up to 68.6% in products which may incur incidental ingestion.

The U.S. Pharmacopeia-National Formulary (USP-NF) standards state that the amount of any individual impurity in glycerin cannot exceed 0.1%, and that the total for all impurities, including diethylene glycol and ethylene glycol, must not exceed 1%.

The technical data sheet for the raw material for this product indicates that the product is made to USP/EP standards.

Glycerin is rapidly absorbed in the intestine and stomach. Glycerol is phosphorylated to alpha-glycerophosphate by glycerol kinase predominantly in the liver (80-90%) and kidneys (10-20%) and incorporated in the standard metabolic pathways to form glucose and glycogen. Glycerin is also naturally occurring in all animals and plant matter as glycerides in fats and oils, or, in intracellular spaces as lipids<sup>1</sup>.

According to the CIR glycerine has low acute oral and dermal toxicity (LD50 27,200 mg/kg and >18,700 mg/kg bw/day respectively) and undiluted glycerine is non irritating to the eyes and skin in testing performed on rabbits. Glycerin was negative for genotoxicity in a barrage of in vitro and in vivo toxicity tests. Natural and synthetic glycerine was non sensitising in tests performed in guinea pigs<sup>1</sup>.

According to the OECD SIDS report for glycerol there was no concern for carcinogenicity in 2-year dietary studies (up to 20% glycerine in diet) equivalent to 10,000 mg/kg bw/day. This was determined

to be the NOAEL by the OECD report. Glycerin was tested in a developmental toxicity test in rats, mice and rabbits. The NOAEL was >2000 mg/kg bw/day the highest dose tested<sup>2</sup>.

The CIR panel concluded that glycerin is safe when used at present practices of use and concentration. Glycerin not restricted according to Regulation (EC) No. 1223/2009. The use of glycerin is acceptable in this product type and application.

#### References:

1. CIR, Safety Assessment of Glycerin as Used in Cosmetics, 2015
2. SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002

#### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

#### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
Acute oral toxicity	OECD 401	Rat LD <sub>50</sub> : >27,200 mg/kg	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Prior to 1953
Acute dermal toxicity	OECD 402	Rat LD <sub>50</sub> : >18,700 mg/kg	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Prior to 1953
Skin irritation	OECD 404	Rabbit: Undiluted non irritating	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Prior to 1971
Eye irritation	OECD 405	Rabbit: Undiluted non irritating	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Prior to 1953
Two-Generation Reproduction Toxicity Study	OECD 416	NOAEL maternal & foetal rat: >2000 mg/kg bw/day	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Prior to 1953
Carcinogenicity	Non guideline study	NOAEL rat: >10,000 in the diet. 2 year study.	Secondary source: SIDS Initial Assessment Report





			For SIAM 14 Paris, France, 26-28 March 2002  Animal test date: Prior to 2002
<b>Bacterial mutagenicity</b>	OECD 471	Not mutagenic $\pm 59$	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Non animal test method
<b>In Vitro Mammalian Mutagenicity Test</b>	OECD 476	Negative up to cytotoxic dose levels.	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Non animal test method
<b>Mammalian Bone Marrow Chromosome Aberration Test</b>	OECD 475	Negative up to cytotoxic dose levels.	Secondary source: SIDS Initial Assessment Report For SIAM 14 Paris, France, 26-28 March 2002 Animal test date: Non animal test method

## Ingredient Profile: Illite

**CAS number:** 12173-60-3 **EC number:** N/A  
**INCI Name:** Illite  
**Pseudonyms:** N/A  
**Structure:** N/A **Image:** 

**CLP Hazard classification(s):** Not classified  
**REGULATION (EC) No 1223/2009** Not restricted.  
**Other regulatory statuses:** N/A

INCI Name	Blue Color & Pos with Clay Soap (% water)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Level Systemic: Preservative (Priority 1 view)	Maximum Level Systemic: Fragrance (mg/kg bodyweight)	Potential of Systemic Toxicity (mg/kg bodyweight)	Margin of Exposure	Apply skin penetration data? (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100)	skin permeation (%)	Chemical impurities (mg/kg)	NIHSL	Safety Factor	ADL/CEL	Acceptable Exposure Level (mg/kg)
Illite	0.3752	12173-60-3	N/A	Abrasive, Absorbent, Anticaking, Bulking	N/A	0.37522	0.00163	No Data		2	100	0.006	No Data	300		

Illite refers to a group of clay sized micas that have a higher lattice water content and lower potassium content than mica. It is used as an abrasive agent, absorbent agent, anti-caking agent and bulking agent in cosmetic products.

According to an EFSA report in illite clays as an animal feed additive<sup>1</sup>, illite is not expected to be absorbed through the skin or when ingested. Illite was not genotoxic *in vitro* or *in vivo*. Illite was not irritating to the eyes and skin of rabbits. Skin sensitisation may occur due to nickel contamination. Heavy metal contamination should be controlled in cosmetic grade Illite.

### Summary:

The concentration and use of Illite is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

1. EFSA Journal 2016;14(1):4342

### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.


Test type:	Guideline:	Result	Source
------------	------------	--------	--------



<b>Acute inhalation toxicity</b>	OECD 403	LC <sub>50</sub> rat > 3.9 mg/L	Secondary source: EFSA Journal 2016;14(1):4342 Non animal test data. Animal test date: Not declared
<b>Skin irritation</b>	OECD 404	Rabbit: Non irritating at up to 100%	Secondary source: EFSA Journal 2016;14(1):4342 Non animal test data. Animal test date: Not declared
<b>Eye irritation</b>	OECD 405	Rabbit: Non irritating at up to 100%	Secondary source: EFSA Journal 2016;14(1):4342 Non animal test data. Animal test date: Not declared
<b>In vitro bacterial reverse mutation test</b>	OECD 471	Not genotoxic 5000 µg/plate ±S9.	Secondary source: EFSA Journal 2016;14(1):4342 Non animal test data.
<b>In Vitro mammalian chromosome aberration test</b>	OECD 473	No chromosomal aberrations were observed in CHO cells.	Secondary source: EFSA Journal 2016;14(1):4342 Non animal test data.
<b>In vivo mammalian erythrocyte micronucleus test</b>	OECD 474	Not genotoxic to mice at up to 2000 mg/kg	Secondary source: EFSA Journal 2016;14(1):4342 Not declared.



## Ingredient Profile: Juniperus Mexicana Wood Oil

**CAS number:** 91722-61-1 **EC number:** 294-461-7  
**INCI Name:** Juniperus Mexicana Wood Oil  
**Pseudonyms:** Juniperus Mexicana Wood Oil  
**Structure:** N/A **Image:** 

**CLP Hazard classification(s):** Not classified  
**REGULATION (EC) No 1223/2009** Not restricted.  
**Other regulatory statuses:** N/A

INCI Name	Blue Cedar & Pine with Oats Soap (% w/w)	CAS Number	EC Number	Paraphrase	Restrictions	Maximum Level Synthetic Preserved in Product (% w/w)	Exposure (% Dose (mg/kg bw/d))	Point of Departure (mg/kg bw/d)	Margin of Exposure	Apply skin penetration data (if available) to estimate systemic exposure	Skin penetration (%)	Dermal exposure (mg/kg bw/d)	PERIL	Safety Factor	AE/CEL	Acceptable Exposure Level (mg/kg bw/d)
Juniperus Mexicana Wood Oil	0.6507	91722-61-1	294-461-7	Perfuming	N/A	0.65072	0.00285	No Data	2	100	0.010	No Data	300			

Juniperus Mexicana Wood Oil is an essential oil obtained from the wood of the Juniper, Juniperus mexicana, Cupressaceae.

Jasminum Officinale (Jasmine) Oil is considered to be Generally Recognised As Safe in food by the USFDA (21CFR182.20).

According to Tisserand<sup>1</sup> Juniperus Mexicana Wood Oil has low acute oral and dermal toxicity. Juniperus Mexicana Wood Oil was not irritating to the skin of rabbits. In a HRIPT in 25 individuals 8% Juniperus Mexicana Wood Oil was not irritating or sensitising.

### Summary:

The concentration and use of Juniperus Mexicana Wood Oil is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

1. Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013.

### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to

REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
Acute oral toxicity	OECD 401	Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976
Acute dermal toxicity	OECD 402	Rabbit LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976
Skin irritation	OECD 404	Rabbit: Non irritating at up to 100%	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976

## Ingredient Profile: Kaolin

**CAS number:** 1332-58-7      **EC number:** N/A  
**INCI Name:** 1332-58-7  
**Pseudonyms:** China Clay, CI 77004  
**Structure:**  $\text{Al}_2\text{Si}_2\text{O}_5(\text{OH})_4$       **Image:**



**CLP Hazard classification(s):** H373 – May cause damage to organs (lungs) through prolonged or repeated exposure

**REGULATION (EC) No 1223/2009**      IV/119

**Other regulatory statuses:** Food:  
USFDA: GRAS, approved direct food additive (21CFR184.1077).  
JEFCA: ADI not restricted  
EU food additive E559

INCI Name	Blue Color & Prec with Data Soap (% w/w)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Allowable Systemic Exposure to Systemic Proven(s) (% Dose (mg/kg bw/day))	Route of Exposure (mg/kg bw/day)	Margin of Exposure	Apply when potential hazard from systemic exposure is not well understood	Skin protection (mg/kg bw/day)	General exposure (mg/kg bw/day)	Health	Safety Factor	ADL/CEL	Acceptable Exposure Level against
Kaolin	0.5953	1332-58-7	316-194-1	Abrasive, Absorbent, Anticaking, Bulking, Cosmetic Colorant, Opacifying	IV/119	0.5953	0.00258	10000	2076214	100	0.009	No Data	300		

Kaolin is a native hydrated aluminium silicate. Kaolin is a natural component of the soil and occurs widely in ambient air. Kaolin mining and refining involve considerable exposure, and significant exposure is also expected in paper, rubber, and plastic production.

Kaolin is used as an absorbent agent, anticaking agent, bulking agent, opacifying agents, skin protectants, and slip modifiers.

Kaolin is an approved indirect food additive by the USFDA (21CFR186.125) and is considered to be Generally Recognised As Safe (GRAS). Kaolin is approved as an OTC ingredient as a digestive aid, antidiarrheal aid (21CFR310.545, 21CFR335.10).

Kaolin may cause mechanical irritation to the eyes and skin. In animal models kaolin was not irritating to the skin<sup>1</sup>.

According to the CIR review kaolin is used at levels of up to 84% in face masks, up to 36% in foundations, up to 30% in lipsticks, up to 25% in moisturizers and up to 25% in suntan gels/creams. The CIR concluded that there is a concern regarding occupational exposure to kaolin via inhalation which has been related to case reports of fibrosis and silicosis in humans. However, in cosmetic preparations inhalation is not expected. It concluded that kaolin was safe as currently used in cosmetics<sup>1</sup>.

Skin sensitisation has not been reported to kaolin despite widespread use in medicines, cosmetics and food/food contact materials. According to suppliers MSDSs skin sensitisation was not observed in LLNA testing (details not provided). Skin sensitisation is not expected.



Orally kaolin is considered to be relatively inert, the only toxicological effects appear to derive from its adsorptive abilities. The lethal dose for humans is considered to be  $>15 \text{ g/kg}^3$ . Kaolin was well tolerated in a 90 day oral study up to 20% in the diet ( $\sim 10,000 \text{ mg/kg bw/day}$ )<sup>1</sup>. Systemic toxicity is not expected in the current application.

Regarding inhalation risk, it is well established that clay minerals may cause long term lung damage, usually observed with occupational exposure. According to a WHO report, kaolin inhalation may lead to a relatively benign form of pneumoconiosis, known as kaolinosis. Based on occupational exposure from china clay workers in the UK it has been estimated that “kaolin is at least an order of magnitude less potent than quartz”.

In the proposed usage it is not anticipated that consumers will be exposed to respirable particles, therefore lung toxicity is not expected.

#### Summary:

The concentration and use of kaolin is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

#### References:

1. IJT 22(Suppl. 1):37-102, 2003
2. Environmental Health Criteria 231, BENTONITE, KAOLIN, AND SELECTED CLAY MINERALS, World Health Organization Geneva, 2005  
[https://www.who.int/ipcs/publications/ehc/ehc\\_231.pdf](https://www.who.int/ipcs/publications/ehc/ehc_231.pdf)
3. CFNP TAP Review for Kaolin Pectin, 2002

#### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
Acute oral toxicity	Not to guideline	Rat LD <sub>50</sub> : 149 g /kg	Secondary source: I.IJT 22(Suppl. 1):37-102, 2003 Animal test date: 1977
Acute dermal toxicity		Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: HSDB database Animal test date:
Dermal irritation	OECD 404	Rabbit: Not irritating	Secondary source: REACH Dossier Animal test date: 2000.
Acute eye irritation	OECD 405	Rabbit: causes mechanical irritation. Moderate eye irritant	Secondary source: HSDB database Animal test date: 2007
Sensitization: Local Lymph Node Assay	OECD 429	Not sensitising	Secondary source: Suppliers MSDS Animal test date: Prior to 2013



<b>3 month inhalation study</b>	Not to guideline	Rats administered 50 mg/rat displayed pulmonary toxicity signs of fibrogenesis	Secondary source: I.JT 22(Suppl. 1):37-102, 2003 Animal test date: 1975
<b>90 day oral study</b>	Not to guideline	Rats fed either a 20% kaolin diet which was either iron supplemented or kaolin alone. There was a significant reduction in haemoglobin, hemaocrit and RBC numbers. This was not seen in the iron supplemented diet, suggesting toxicity was related to adsorption.	Secondary source: I.JT 22(Suppl. 1):37-102, 2003 Animal test date: 1977
<b>Supporting data</b>	ADI	Not restricted	Joint FAO/WHO Expert Committee on Food Additives which met in Geneva, 25 June - 4 July 1973

## Ingredient Profile: Montmorillonite

**CAS number:** 1318-93-0 **EC number:** 215-288-5 (I)  
**INCI Name:** Montmorillonite  
**Pseudonyms:** N/A  
**Structure:** N/A **Image:**



**CLP Hazard classification(s):** Not classified  
**REGULATION (EC) No 1223/2009** Not restricted.  
**Other regulatory statuses:** N/A

INCI Name	Blue Color & Blue with Gray Strip (%)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Local Systemic Exposure (mg/kg body weight)	Polar of Disposition (mg/kg body weight)	Margin of Exposure	Apply skin penetration data (if available) to estimate dose of exposure	Skin penetration (%)	Oral exposure (mg/kg body weight)	MSL	Safety Factor	ASL/CEL	Acceptable Exposure Level (mg/kg)
Montmorillonite	0.0000	1318-93-0	215-288-5	Absorbent, Bulking, Emulsion Stabilizing, Stabilizing, Viscosity Controlling	N/A	0.0000	0.0001	1000	7.68/59%	100	0.000	No Data	300		

Montmorillonite is a complex aluminium/magnesium silicate clay. Montmorillonite is used as an abrasive agent, absorbent, bulking agent, opacifying agent, and viscosity increasing agents.

Montmorillonite has been investigated for its absorptive properties. In a study in Ghana, absorption of aflatoxin was investigated ingesting 1.5 g/day Montmorillonite or a placebo for 14 days<sup>1</sup>. There was a significant reduction in aflatoxin metabolites with Montmorillonite ingestion. There were no reported adverse effects. In another clinical trial 3 grams per day were well tolerated for 2 weeks<sup>2</sup>.

Montmorillonite when compared to similar clays such as magnesium aluminium silicate, kaolin and hectorite are not likely to cause genotoxicity, skin irritation or sensitisation. Eye irritation by mechanical irritation is expected<sup>3</sup>.

Montmorillonite may contain fibres and silica which are carcinogenic when inhaled<sup>3</sup>. As the product is not likely to generate respirable particles, inhalation toxicity is not expected. The CIR<sup>3</sup> concluded that Montmorillonite was safe as used in cosmetic products, respirable particles were unlikely to be generated under normal cosmetic use. Spray based products need to ensure that respirable particles are not generated.

### Summary:

The concentration and use of Montmorillonite is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

1. Food Additives and Contaminants 22(3):270-9
2. Am J Trop Med Hyg. 2014 Oct 1; 91(4): 777-785
3. IJT 22(Suppl. 1):37-102, 2003



Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

## Ingredient Profile: Pinus Sylvestris Oil

**CAS number:** N/A **EC number:** N/A  
**INCI Name:** Pinus Sylvestris Oil  
**Pseudonyms:** Scots Pine Oil  
**Structure:** N/A **Image:**



**CLP Hazard classification(s):** Not classified

**REGULATION (EC) No 1223/2009** Annex III/I 10: Peroxide value less than 10 mmols/L. This limit applies to the substance and not to the finished cosmetic product.

**Other regulatory statuses:** N/A

INCI Name	Size Color & Pin with Data Sheet (% w/w)	CAS Number	EC Number	Preservative	Maximum Level Systemic Present in Product (% w/w) (MHL)	Maximum Level Systemic Present in Product (% w/w) (MHL)	Peroxide of Oxidation (mg/kg)	Margin of Safety	Apply skin penetration data? (Yes/No)	Skin penetration (%)	Dermal exposure (mg/kg)	NEEL	Toxicity Factor	ADL/CEL	Acceptable Exposure Level (mg/kg)
Pinus Sylvestris Oil	0.6307 04012 35 1 / 94266 46 5	201 679 2 / 304 455 9		Masking, Perfuming	III/110	0.65872	0.00285 No Data		Yes	100	0.010 No Data		300		

Pinus Sylvestris Oil is the fixed oil obtained from the cone of the pine, Pinus sylvestris. Pinus Sylvestris Oil is used as a fragrance ingredient in cosmetic products.

Pinus Sylvestris Oil is approved for use as a direct additive in food by the USFDA (21CFR172.510).

According to Tisserand<sup>1</sup> Pinus Sylvestris Oil was not irritating to the skin of rabbits when applied undiluted. When tested at 12% on 25 volunteers it was neither irritating nor sensitising. In a study of patients 200 patients with contact dermatitis, 2% Pinus Sylvestris Oil caused reactions in 4 subjects.

### Summary:

The concentration and use Pinus Sylvestris Oil is restricted according to Regulation (EC) No 1223/2009. According to Annex III/I 10: Peroxide value less than 10 mmols/L. This limit applies to the substance and not to the finished cosmetic product. The Responsible Person must ensure that it complies with the requirements of Annex III/I 10. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

- I. Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013.

Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
<b>Acute oral toxicity</b>	OECD 401	Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976
<b>Acute dermal toxicity</b>	OECD 402	Rabbit LD <sub>50</sub> : >5000 mg/kg	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976
<b>Skin irritation</b>	OECD 404	Rabbit: Non irritating at up to 100%	Secondary source: Tisserand, Essential Oil Safety: A Guide for Health Care Professionals, 2nd Edition, 2013. Animal test date: Prior to 1976
<b>In vitro bacterial reverse mutation test</b>	OECD 471	Not genotoxic 5000 µg/plate ±S9.	Secondary source: REACH dossier Non animal test data

## Ingredient Profile: Sodium Chloride

**CAS number:** 7647-14-5 **EC number:** 231-598-3 (I)

**INCI Name:** Sodium Chloride

**Pseudonyms:** Salt, rock salt

**Structure:** NaCl

**Image:**



**CLP Hazard classification(s):** N/A

**REGULATION (EC) No 1223/2009** Not restricted

**Other regulatory statuses:** N/A

INCI Name	Size Color & Pos. with Size Soap (% w/w)	CAS Number	EC Number	Pseudonyms	Risk factors	Maximum Level Systemic Exposure (mg/kg bw/day)	Potential of Systemic Exposure (mg/kg bw/day)	Marginal Exposure	Apply when potential data is not available (mg/kg bw/day)	Systemic exposure (mg/kg bw/day)	Dermal exposure (mg/kg bw/day)	NESTL	Safety Factor	ASUSEL	Acute/Chronic Exposure Level (mg/kg bw/day)
Sodium Chloride	0.0917	7647-14-5	231-598-3	Bulking, Moistening, Oral Care, Viscosity Controlling	N/A	0.09172	0.00001	50	4193346	3	0.001 No Data		300		

Sodium Chloride an inorganic salt. Sodium chloride is the major salt responsible for the salinity of sea water. It is used as a flavouring agent, condiment and food preservative in foods. It is used as a flavouring agent, oral care agent and viscosity increasing agent in cosmetic products.

Sodium chloride is consumed at ~10g/day in Western countries, with the majority of salt coming from processed food and restaurant food. Due to the concern regarding sodium consumption and increased risk of cardiovascular diseases it is recommended to limit salt to less than 3 g/day<sup>1</sup>.

Sodium chloride is not expected to cause irritation to the skin at concentrations of less than 10% according to testing on rabbits, sodium chloride may cause transient eye irritation at similar concentrations. Sodium chloride was not genotoxic in *in vitro* assays

### Summary:

The concentration and use of sodium chloride is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Systemic toxicity is not expected at the proposed level and usage. Local toxicity endpoints such as skin and eye irritation, sensitisation is not expected at the proposed level and usage. There are no toxicological concerns with the proposed application under normal usage scenarios.

### References:

1. He Feng J, Li Jiafu, MacGregor Graham A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials BMJ 2013; 346 :f1325

Specification data:



No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
Acute Oral Toxicity	OECD 401	Rat LD50: 3550 mg/kg	Secondary source: REACH dossier Animal test date: Not declared.
Acute Dermal Toxicity	OECD 402	Rat LD50: >10,000 mg/kg	Secondary source: REACH dossier Animal test date: Not declared.
Dermal Irritation	OECD 404	In contact with intact skin, sodium chloride causes no irritation, however on abraded skin 20% solutions can cause scab and scarring, at 10% slight irritation is observed.	Secondary source: REACH dossier Animal test date: 1954
In Vitro Bacterial Genotoxicity Assay	OECD 471	Negative ±S9	Secondary source: REACH dossier Animal test date: Non animal test method
In vitro Mammalian Cell Micronucleus Test	OECD 487	Negative	Secondary source: REACH dossier Animal test date: Non animal test data

## Ingredient Profile: Sodium Citrate


**CAS number:** 994-36-5 / 6132-04-3 **EC number:** 213-618-2 (I) / 200-675-3 (I)  
(dihydrate) / 68-04-2  
(anhydrous)

**INCI Name:** Sodium Citrate

**Pseudonyms:** Citric Acid, Trisodium Salt

**Structure:**  $C_6H_5O_7 \cdot 3Na$

**Image:**



**CLP Hazard classification(s):** Not classified

**REGULATION (EC) No 1223/2009** Not restricted.

**Other regulatory statuses:** N/A

INCI Name	Blue Circle & Plus with Data Sheet (C104)	CAS Number	EC Number	Classification	Restrictions	Maximum Limit Systemic Product (%)	Exposure (% Dose mg/kg body weight)	Point of Departure (mg/kg body weight)	Margin of Safety	Apply non-quantitative safety limits (mg/kg body weight)	Skin penetration (%)	Dermal exposure (mg/cm²)	MSL	Safety Factor	ADL/CLL	Acceptable Exposure Limit (mg/kg)
Sodium Citrate		68-04-2 / 6132-04-3	700-675-3	Buffering, Chelating, Preserving	N/A	0.15/860	0.001/99	No Data				100	0.007 / No Data	100		

Sodium Citrate is the sodium salt of citric acid. Sodium Citrate is used as a buffering agent, chelating agent, pH adjuster and fragrance ingredients in cosmetic products.

According to the CIR review<sup>1</sup> Sodium Citrate is typically used at up to 10% in leave on products and up to 10% in rinse off products, up to 2% in products used in the eye area, up to 0.4% in products which may be ingested, up to 4% in hair products, up to 0.5% in nail products and up to 1% in products which may be used on the mucous membrane. In a human irritation study Sodium Citrate was not irritating to the skin at 10%<sup>1</sup>. Citric acid and its salts have not reported to be a sensitizer in human studies<sup>1</sup>. Sodium Citrate was not genotoxic in an *in vitro* Ames study.

Upon ingestion it is expected that Sodium Citrate will dissociate into Citric acid and sodium. When orally administered is well absorbed and metabolised. Citric acid is also produced endogenously as a part of normal metabolism, where it completes the breakdown of pyruvate produced from glucose metabolism. Approximately 2 Kg of citric acid is metabolised every day in humans. Citric acid is freely filterable in the kidney and 65-90% of citric acid is reabsorbed<sup>2</sup>. Therefore, as citric acid is present in the diet naturally in addition to synthetic sources, coupled with endogenous production of citric acid, systemic toxicity from cosmetic products containing citric acid/ sodium citrate is not expected.

### Summary:

The concentration and use of Sodium Citrate is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

1. IJT 33(Suppl.2):16-46, 2014

Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
<i>In vitro</i> bacterial reverse mutation test	OECD 471	Not genotoxic 5000 µg/plate ±S9.	Secondary source: IJT 33(Suppl.2):16-46, 2014 Non animal test data.



Index	EC Number	Restriction(s)	Maximum Lead Substances Present in Product(s) (% Dose (mg/kg bodyweight))	Exposure	Point of Exposure (mg/kg bodyweight)	Marginal Exposure	Apply skin permeation data (mg/kg bodyweight) (mg/kg bodyweight)	Non-permeation (mg/kg bodyweight)	Oral exposure (mg/kg bodyweight)	Subcutaneous exposure (mg/kg bodyweight)	Subcutaneous exposure (mg/kg bodyweight)	Subcutaneous exposure (mg/kg bodyweight)	Subcutaneous exposure (mg/kg bodyweight)
009-1	363-097-0	Cleansing, Preserving, Surfactant, Viscosity Controlling	N/A	16.05/101	0.06955	1000	14377	100	0.718/100	100	100	100	100

[illegible]

In soap making: oils such as palm oil are saponified with lye (sodium hydroxide) to make the sodium fatty acid salt and glycerin.

Sodium Palm Kernelate is used as a surfactant and cleansing agent in cosmetic products. *Elaeis Guineensis* (Palm) Oil consists of<sup>2</sup>; up to 44% palmitic acid, up to 0.1% palmitoleic acid, up to 4.5% stearic acid, up to 39.2% oleic acid, up to 10.1% linoleic acid and up to 0.4% linolenic acid. Saponification of olive oil with lye would create sodium palmitate, sodium stearate and their respective sodium salts of the fatty acids. Depending on the superfatting level there may be some unreacted fatty acids.

Vegetable based fatty acids have a long history of safe use in the diet in edible oils, such as rapeseed oil, palm oil, olive oil and other vegetable-based oils. According to JECFA palmitic acid, stearic acid, lauric acid and oleic acid are do not have any safety concerns in the diet<sup>4</sup>. When applied topically fatty acids have been shown to remain mainly on the outer layers of the stratum corneum with little penetration<sup>5</sup>. Therefore, any unreacted fatty acids are not likely to cause systemic toxicity.

Page 42 of 50

For the purposes of margin of safety calculations, a group read across assessment of various fatty acid salts was used. The lowest NOAEL was 1000 mg/kg bw/day and should be suitably conservative for margin of exposure calculations.

**Summary:**

The concentration and use of Sodium Palm Kernelate is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

**References:**

1. Nanoscale Assembly: Chemical Techniques Nanostructure Science and Technology  
Editor: Wilhelm T.S. Huck, Springer Science & Business Media, 2006
2. CIR, Safety Assessment of Plant Derived Fatty Acid Oils, 2017.
3. CIR, Safety Assessment of Fatty Acids & Fatty Acid Salts as Used in Cosmetics, 2019
4. JECFA, WHO Food Additives Series No. 40, 1998.
5. Patzelt, A & Lademann, J & Richter, H & Darvin, Maxim & Schanzer, S & Thiede, Gisela & Sterry, Wolfram & Vergou, Theognosia & Hauser, Matthias. (2011). In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 18. 364-9. 10.1111/j.1600-0846.2011.00578.x.
6. 21CFR172.863
7. Re-evaluation of sodium, potassium and calcium salts of fatty acids (E 470a) and magnesium salts of fatty acids (E 470b) as food additives, 2018.

**Specification data:**

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

**Supporting test data:**


The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
<b>Acute oral toxicity</b>	OECD 401	Read across: Calcium stearate. Rat LD <sub>50</sub> : >2000 mg/kg	Secondary source: Safety Assessment of Fatty Acids & Soaps as Used in Cosmetics Animal test date: Prior to 2013
<b>Acute dermal toxicity</b>	OECD 402	Read across: Lithium stearate. Rat LD <sub>50</sub> : >2000 mg/kg	Secondary source: Safety Assessment of Fatty Acids & Soaps as Used in Cosmetics Animal test date: Prior to 2013





<p><b>Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test</b></p>	<p>OECD 422</p>	<p>Read across: Calcium stearate NOAEL &gt;1000 mg/kg bw/day systemic effects. NOAEL 100 mg/kg bw/day for local effects of ulceration and inflammation of the skin. Lithium stearate &gt;1000 mg/kg bw/day. No reproductive toxicity observed in either study.</p>	<p>Secondary source: Safety Assessment of Fatty Acids &amp; Soaps as Used in Cosmetics</p> <p>Animal test date: Prior to 2013.</p>
---	-----------------	--	--



SWIFT FOX  
CONSULTING



## Ingredient Profile: Sodium Palmate

**CAS number:** 61790-79-2 **EC number:** 263-162-3 (I)  
**INCI Name:** Sodium Palmate  
**Pseudonyms:**  
**Structure:** N/A **Image:** N/A

**CLP Hazard classification(s):** Not classified

**REGULATION (EC) No 1223/2009** Not restricted.

**Other regulatory statuses:** N/A

INCI Name	Blue Color & Blue with Orange Strip (Color)	CAS Number	EC Number	Function(s)	Restrictions	Maximum Lead Content (ppm)	Maximum Lead Content (ppm) (if not specified)	Point of Departure (mg/kg body weight)	Margin of Exposure	Apply skin penetration data if not available (mg/kg body weight)	Dermal exposure (mg/kg body weight)	Systemic exposure (mg/kg body weight)	AD/CEL	Acceptable Exposure (mg/kg body weight)
Sodium Palmate	NA	61790-79-2	763-162-3	Cleaning, Emulsifying, Surfactant, Visibly Controlling	N/A	51.6886	0.73377	1000	0.000	100	0.067 (No Data)	300		

Sodium Palmate is the sodium salt of the acids derived from *Elaeis Guineensis* (Palm) Oil.

It is used as a soap, surfactant and emulsifying agent in cosmetic products. In soap making; oils such as palm oil are saponified with lye (sodium hydroxide) to make the sodium fatty acid salt and glycerin.

The earliest evidence of soap making comes from soap deposits found in Egypt dated to ~2800 BC, inscriptions state the fats were boiled with ashes. There is evidence from 1500 BC that soaps were used for washing and treating skin diseases<sup>1</sup>. Soaps made with vegetable oils or animals fats have a long history of safe use for skin cleansing purposes.

Sodium Palmate is approved as indirect food additive by the USFDA (21CFR175.105, and 21CFR176.170).

Sodium Palmate is used as a surfactant and cleansing agent in cosmetic products. *Elaeis Guineensis* (Palm) Oil consists of<sup>2</sup>; up to 44% palmitic acid, up to 0.1% palmitoleic acid, up to 4.5% stearic acid, up to 39.2% oleic acid, up to 10.1% linoleic acid and up to 0.4% linolenic acid. Saponification of olive oil with lye would create sodium palmitate, sodium stearate and their respective sodium salts of the fatty acids. Depending on the superfatting level there may be some unreacted fatty acids.

The CIR review<sup>2</sup> determined that Sodium Laurate/Linoleate/Oleate/Palmitate (major constituents of sodium palmate)<sup>3</sup> is used at up to 84.7% in rinse off products, up to 74.5% in leave on products, up to 74.5% in baby products and up to 84.7% in products applied to the mucous membranes.

Vegetable based fatty acids have a long history of safe use in the diet in edible oils, such as rapeseed oil, palm oil, olive oil and other vegetable-based oils. According to JECFA palmitic acid, stearic acid, lauric acid and oleic acid are do not have any safety concerns in the diet<sup>4</sup>. When applied topically fatty acids have been shown to remain mainly on the outer layers of the stratum corneum with little penetration<sup>5</sup>. Therefore, any unreacted fatty acids are not likely to cause systemic toxicity.

The salts of fatty acids are all approved food additives in the US and EU<sup>6,7</sup>. Upon ingestion these sodium salts are expected to dissociate in the gastric tract to fatty acid carboxylates and sodium salts. Sodium

stearate has demonstrated the ability to penetrate the skin<sup>7</sup>. it is expected that other sodium fatty acid salts may also penetrate the skin.

For the purposes of margin of safety calculations, a group read across assessment of various fatty acid salts was used. The lowest NOAEL was 1000 mg/kg bw/day and should be suitably conservative for margin of exposure calculations.

#### Summary:

The concentration and use of Sodium Palmate is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

#### References:

1. Nanoscale Assembly: Chemical Techniques Nanostructure Science and Technology  
Editor Wilhelm T.S. Huck, Springer Science & Business Media, 2006
2. CIR, Safety Assessment of Plant Derived Fatty Acid Oils, 2017.
3. CIR, Safety Assessment of Fatty Acids & Fatty Acid Salts as Used in Cosmetics, 2019
4. JECFA, WHO Food Additives Series No. 40, 1998.
5. Patzelt, A & Lademann, J & Richter, H & Darvin, Maxim & Schanzer, S & Thiede, Gisela & Sterry, Wolfram & Vergou, Theognosia & Hauser, Matthias. (2011). In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 18. 364-9. 10.1111/j.1600-0846.2011.00578.x.
6. 21CFR172.863
7. Re-evaluation of sodium, potassium and calcium salts of fatty acids (E 470a) and magnesium salts of fatty acids (E 470b) as food additives, 2018.

#### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

#### Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.




Test type:	Guideline:	Result	Source
Acute oral toxicity	OECD 401	Read across: Calcium stearate. Rat LD <sub>50</sub> : >2000 mg/kg	Secondary source: Safety Assessment of Fatty Acids & Soaps as Used in Cosmetics Animal test date: Prior to 2013
Acute dermal toxicity	OECD 402	Read across: Lithium stearate. Rat LD <sub>50</sub> : >2000 mg/kg	Secondary source: Safety Assessment of Fatty Acids & Soaps as Used in Cosmetics Animal test date: Prior to 2013
Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test	OECD 422	Read across: Calcium stearate NOAEL >1000 mg/kg bw/day systemic effects. NOAEL 100 mg/kg bw/day for local effects of ulceration and inflammation of the skin. Lithium stearate >1000 mg/kg bw/day. No reproductive toxicity observed in either study.	Secondary source: Safety Assessment of Fatty Acids & Soaps as Used in Cosmetics  Animal test date: Prior to 2013.



## Ingredient Profile: Tetrasodium Glutamate Diacetate

**CAS number:** 51981-21-6 **EC number:** 257-573-7  
**INCI Name:** Tetrasodium Glutamate Diacetate  
**Pseudonyms:** Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate  
**Structure:**  $C_9H_9NO_8Na_4$  **Image:**



**CLP Hazard classification(s):** Not classified  
**REGULATION (EC) No 1223/2009** Not restricted.  
**Other regulatory statuses:** N/A

INCI Name	Stock Color & Size with Care	CAS Number	EC Number	Pseudonym	Restrictions	Maximum Level Systemic Exposure (mg/kg bw/day)	Potential of Systemic Exposure (mg/kg bw/day)	Margin of Exposure	Apply skin penetration data if not available	Skin penetration (g)	Dermal exposure (g/kg)	NESTL	Safety Factor	ASUSEL	Acute toxicity Level (g/kg)
Tetrasodium Glutamate Diacetate	0.4500	51981-21-6	257-573-7	Chelating	N/A	0.45060	0.00199	300	15000	100	0.007	No Data	300		

Tetrasodium Glutamate Diacetate is used as a chelating agent in cosmetic products.

Tetrasodium Glutamate Diacetate has low acute oral toxicity. Tetrasodium Glutamate Diacetate is not irritating to the skin or eye in animal models when applied undiluted. Tetrasodium Glutamate Diacetate is not a skin sensitizer in a guinea pig maximisation assay when tested at up to 50% concentrations. Tetrasodium Glutamate Diacetate is not genotoxic *in vitro* or *in vivo*. Tetrasodium Glutamate Diacetate was tested in a 90 oral toxicity test in rats, the NOAEL was 300 mg/kg bw/day.

### Summary:

The concentration and use of Tetrasodium Glutamate Diacetate is not restricted according to Regulation (EC) No 1223/2009. The concentration and usage of this ingredient is consistent with industry norms. Under normal conditions of use systemic toxicity is not expected. Local toxicity endpoints such as; skin and eye irritation, skin sensitization, and phototoxicity are not expected.

### References:

1. Cosmetic Ingredient Review Expert Panel, Scientific Literature Review for Public Comment, Safety Assessment of Beta-Alanine Diacetic Acid and Tetrasodium Glutamate Diacetate Used in Cosmetics, 2019.

### Specification data:

No specification test data was provided the responsible person must ensure that the ingredient is food or cosmetic grade.

Supporting test data:

The data below is based on *in vivo* and *in vitro* data to support the safety assessment. Any animal testing data listed below has been obtained from publicly available literature sources. According to REGULATION (EC) No 1223/2009 and Council Directive 76/768/EEC animal testing is prohibited for cosmetic products and ingredient past the prescribed timescales.

Test type:	Guideline:	Result	Source
<b>Acute oral toxicity</b>	OECD 401	Rat LD <sub>50</sub> : >5000 mg/kg	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 1994
<b>Skin irritation</b>	OECD 404	Rabbit: Non irritating at up to 100%	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 1994
<b>Eye irritation</b>	OECD 405	Rabbit: Non irritating at up to 100%	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 1994
<b>Skin sensitisation</b>	OECD 406	Not sensitising at up to 50% in guinea pigs	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 1995
<b>Repeated dose 90-day oral toxicity study in rodents</b>	OECD 408	Rats rat 0, 100, 300 and 1000 mg/kg bw/day. NOAEL 300 mg/kg bw/day	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 2007
<b><i>In vitro</i> bacterial reverse mutation test</b>	OECD 471	Not genotoxic 5000 µg/plate ±S9.	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Non animal test data.
<b><i>In vivo</i> mammalian erythrocyte micronucleus test</b>	OECD 474	Not genotoxic at 400 mg/kg	Secondary source: ECHA Dossier for Tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate Animal test date: Prior to 1995



## Annex II – Fragrance Information

The product contains the following essential oils:

Common name	INCI name	Supplier(s)	Restrictions
Sweet Orange Essential Oil	Citrus Aurantium Dulcis Peel Oil	Mystic Moments	N/A
Cedarwood USA, Essential Oil	Juniperus Mexicana Wood Oil	Mystic Moments	N/A
Pine Essential Oil	Pinus Sylvestris Oil	The Soapery	N/A

Substitution of essential oil suppliers not named above must be substituted with similar grades and the INCI name must not change. The Responsible Person must comply with restrictions listed above.

Allergen declarations in this report are based on the information on the date of submission. It is the duty of the Responsible Person to ensure that the ingredient and allergen declarations are correct on the label. It is the duty of the Responsible Person to check raw material information for changes and update labelling accordingly.

For the EU:

Cosmetic products containing additional allergens listed in COMMISSION REGULATION (EU) 2023/1545 will need to be declared on the labelling, when its concentration exceeds:

— 0,001 % in leave-on products

— 0,01 % in rinse-off products.

Products that do not comply with the restriction(s) may be placed on the Union market until 31 July 2026 and made available on the Union market until 31 July 2028. It is the duty of the Responsible Person when placing a cosmetic on sale in the EU to comply with this requirement by the implementation date.

## Annex III

This report is only valid for the formulation(s) submitted herein, should re-formulation occur re-assessment will be necessary.

This report does not cover food imitation, which is prohibited for cosmetic products. This report does not cover medical claims which are prohibited for cosmetic products.

This report covers the Regulation (EC) No. 2009/1223, if the product is marketed in a way is out of scope of the Cosmetic Regulations, for example but not limited to; Biocides (Regulation (EU) No 528/2012), detergents Regulation (EU) 648/2004 or as a toy and relevant safety requirements Regulation (EU) 2009/48/EC The Responsible Person accepts all liability and responsibility for ensuring that their products comply with all of the relevant regulations that apply to their product(s).

The Responsible Person is responsible for ensuring that other elements of the Regulation (EC) No. 2009/1223 such as but not limited to; manufacture to GMP, maintenance/update of the Product Information File, reporting of Serious Undesirable Effects and labelling requirements.

Swift Fox Ltd is not liable for any damage or injury resulting from use of this product.

The validity of the report depends on the disclosure by the manufacturers of the raw materials, packaging and the manufacturer of the finished products.